Literature DB >> 25563462

Argon laser-assisted treatment of benign eyelid lesions.

Şafak Korkmaz1, Feyzahan Ekici, Sabahattin Sül.   

Abstract

We investigated the treatment of benign eyelid lesions with argon laser as an alternative therapy to surgical excision. The charts of 73 patients with 95 lesions treated with argon laser photocoagulation were reviewed retrospectively. In all patients, the procedure was performed for cosmetic reasons. The laser spot size ranged from 50 to 200 μm, the power varied from 300 to 700 mW, and the exposure time ranged between 0.1 and 0.2 s. The lesions were mostly located on the upper eyelid (66%); the lid margin was involved in 30 cases. The mean follow-up time was 7.2 ± 3.5 months (range 3-15 months). A histopathological diagnosis was confirmed for 81 lesions (85.3%). All patients were satisfied with the cosmetic result. No intraoperative complications occurred, and none of the patients complained of pain during laser application. All wounds epithelialized in 3-4 weeks with skin that appeared normal. Hypopigmentation of the treated areas were observed in three cases. No recurrence occurred during the follow-up period. Argon laser-assisted benign eyelid tumor excision is a useful, cheap, accessible, and well-tolerated alternative to traditional surgery.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25563462     DOI: 10.1007/s10103-014-1708-z

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  18 in total

1.  Xanthelasma palpebrarum: treatment with the erbium:YAG laser.

Authors:  C Borelli; P Kaudewitz
Journal:  Lasers Surg Med       Date:  2001       Impact factor: 4.025

2.  Laser microsurgery for superficial T1-T2 basal cell carcinoma of the eyelid margins.

Authors:  G Bandieramonte; P Lepera; D Moglia; A Bono; C De Vecchi; F Milani
Journal:  Ophthalmology       Date:  1997-07       Impact factor: 12.079

3.  A new technique: argon green laser-Nd:YAG laser combination for the treatment of premacular haemorrhage.

Authors:  Sinan Emre; Selim Doganay; Soner Demirel; Ahmet Tasar
Journal:  Acta Ophthalmol       Date:  2008-10-07       Impact factor: 3.761

4.  Recurrent trichiasis: treatment with laser photocoagulation.

Authors:  J Berry
Journal:  Ophthalmic Surg       Date:  1979-07

5.  Treatment of trichiasis with argon laser.

Authors:  E Başar; H Ozdemir; S Ozkan; E Cicik; C Mirzataş
Journal:  Eur J Ophthalmol       Date:  2000 Oct-Dec       Impact factor: 2.597

6.  [Treatment of benign eyelid conditions with Argon laser].

Authors:  J-M Ruban
Journal:  J Fr Ophtalmol       Date:  2003-01       Impact factor: 0.818

7.  Treatment of xanthelasma palpebrarum with argon laser photocoagulation. Argon laser and xanthelasma palpebrarum.

Authors:  Emel Basar; Halit Oguz; Hakan Ozdemir; Sehirbay Ozkan; Hasim Uslu
Journal:  Int Ophthalmol       Date:  2004-01       Impact factor: 2.031

8.  Argon laser therapy of benign tumors of the eyelid.

Authors:  T M Wohlrab; J M Rohrbach; C Erb; T Schlote; M Knorr; H J Thiel
Journal:  Am J Ophthalmol       Date:  1998-05       Impact factor: 5.258

9.  Laser conjunctivoplasty: a new technique for correction of mild medial ectropion.

Authors:  Sanjeev Nainiwal; Harsh Kumar; Atul Kumar
Journal:  Orbit       Date:  2003-09

10.  Argon laser photoablation of superficial conjunctival nevus: results of a 3-year study.

Authors:  Kyung-Hoon Shin; Jae-Hyeong Hwang; Ji-Won Kwon
Journal:  Am J Ophthalmol       Date:  2013-02-06       Impact factor: 5.258

View more
  2 in total

1.  Evaluation of Meibomian Gland Function after Therapy of Eyelid Tumors at Palpebral Margin with Super Pulse CO2 Laser.

Authors:  Songjiao Zhao; Jueni Duan; Jing Zhang; Lan Gong
Journal:  Dis Markers       Date:  2022-01-17       Impact factor: 3.434

2.  Modified argon laser therapy for benign tumor of the eyelid.

Authors:  Jisang Han; Shin-Hyo Lee; Chul Young Choi; Ramin Khoramnia; Jaemin Kim; Hyun Jin Shin
Journal:  BMC Ophthalmol       Date:  2022-09-24       Impact factor: 2.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.